Test Price
2,800 AED✅ Home Collection Available
CHRNA1 Gene Slow‑Channel Congenital Myasthenic Syndrome Genetic Test in UAE | 2,800 AED
Executive Summary & Core Metrics
Clinical & Operational Excellence
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑accredited Next‑Generation Sequencing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Complimentary telephonic post‑test clinical interpretation by a genetics specialist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 – coverage confirmed within 15 minutes.
Test Overview & Methodology
The CHRNA1 slow‑channel congenital myasthenic syndrome (CMS) genetic test uses next‑generation sequencing to detect pathogenic variants in the acetylcholine receptor alpha‑1 subunit gene, directly linking genotype to neuromuscular junction dysfunction. This advanced assay supports definitive diagnosis, precise subtyping, and personalised management for neonatal, paediatric, and adult‑onset CMS.
| Parameter | Our CHRNA1 NGS Test | Closest Alternative (Standard CMS Panel) |
|---|---|---|
| Methodology | Next‑Generation Sequencing with full CHRNA1 coding region coverage; complemented by transcriptome/RNA sequencing | Targeted Sanger sequencing or multi‑gene panel that may omit deep intronic regions |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Variant Detection Sensitivity | 99.9% for SNVs and small indels causing slow‑channel CMS | ~85% sensitivity, with higher chance of missing rare variants |
| Pre‑test Counselling | Mandatory genetic counselling session with pedigree charting (included) | Often limited to verbal consent; no formal pedigree documentation |
Physician Insight & Safety Protocols
“Genetic confirmation of slow‑channel CMS is essential for guiding targeted therapy and avoiding inappropriate treatments. I personally review every case to ensure accurate genotype‑phenotype correlation and optimal family counselling.”
Medication Advisory
⚠ Medication Warning
Never stop or alter prescribed medications without consulting your physician. Sudden withdrawal of anticholinesterases or immunosuppressants may trigger a severe deterioration in neuromuscular function.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria & Emergency Red Flags
- Inappropriate for: Asymptomatic general population screening without a compelling family history or clinical indication; direct‑to‑consumer unsupervised testing in minors without legal guardian consent as per Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flags – seek immediate medical attention (call 998): Acute respiratory distress, inability to swallow saliva or speak (severe bulbar weakness), sudden generalised weakness with oxygen desaturation, apnoeic episodes, or stridor. These may indicate an impending myasthenic crisis and require urgent hospitalisation.
Patient FAQ & Clinical Guidance
1. What exactly does the CHRNA1 gene test diagnose?
This NGS test confirms slow‑channel congenital myasthenic syndrome by detecting CHRNA1 mutations that prolong acetylcholine receptor opening. The assay identifies missense and frameshift variants known to cause the slow‑channel phenotype—characterised by repetitive discharges on electromyography and progressive limb‑girdle weakness. Results enable differentiation from other CMS subtypes and myasthenia gravis, directly impacting treatment choices.
2. How is the sample collected and what does it involve?
A blood or DNA sample is collected at home by a certified phlebotomist and sequenced for CHRNA1 variants. You can provide whole blood, a buccal swab, or an FTA card drop. Our hospital‑grade mobile team arrives at your preferred address (8 AM–11 PM), maintains cold‑chain integrity, and completes the draw in under 15 minutes. The entire process complies with UAE PDPL data privacy mandates.
3. When will I receive results and what should I do next?
Results are ready in 3–4 weeks and must be interpreted by a neurologist or genetic counsellor. You will receive a secure, ISO‑authenticated report listing the detected CHRNA1 variant, its clinical significance, and carrier status. After that, a complimentary tele‑guidance session with a DHA‑licensed physician is scheduled to explain findings, discuss management, and plan family cascade testing if needed.
UAE Regulatory & Data Privacy Adherence
Trust & Compliance: This test is performed under DHA Facility License No. 1143 and adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and processed with your explicit consent in accordance with UAE federal privacy regulations.
Clinical & Logistical Metadata
| Test Name | CHRNA1 Gene Slow‑Channel Congenital Myasthenic Syndrome Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood, Buccal Swab, or FTA Card |
| Methodology Used | Next‑Generation Sequencing (NGS) with full CHRNA1 coding region coverage |
| ICD-10-CM Code | G70.2 (Congenital myasthenic syndrome) |
| LOINC Code | 94222-8 (CHRNA1 gene mutation analysis) |
| DHA Facility License & Laboratory Address | License No. 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians